Prior to joining ActivBiotics, Dr. Sternlicht was Executive Medical Director at the Medicines Company where he organized and led the initial development of Angiomax® (bivalirudin) in cardiac surgery and the successful in-licensing of Clevelox® (clevidipine) from Astra Zeneca. Andrew trained in anesthesiology and surgery, and is a board certified anesthesiologist, who currently on staff at St. Elizabeth's Medical Center in Boston, where he founded the Multidisciplinary Pain Management Center. Dr. Sternlicht has been an industry consultant and has served on the strategic advisory boards of Baxter, Elan, Algos Pharmaceutical, and Vital Signs, Inc. He is an Assistant Professor at Tufts University School of Medicine and received his M.D. from Yale, his M.A. in Biology from the University of Pennsylvania, as well as receiving post-graduate business training at the Wharton School.